READING, 7th June 2007 – Archimedes Pharma Ltd (“Archimedes”), a European specialty pharmaceutical company, today presented new clinical data from a Phase II study of Nasalfent®, an innovative fentanyl citrate nasal spray aimed at providing a fast, effective and convenient treatment for breakthrough cancer pain. Data were presented at the 10th Congress of the European Association for Palliative Care (EAPC) in Budapest showing that Nasalfent can give significant, clinically meaningful levels of pain relief and a reduction in pain intensity within 5 minutes of dosing.
